While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings guidance for the full-year 2022, while trimming annual revenue outlook.
from RTT - Earnings https://ift.tt/Du2RQUt
via IFTTT
No comments:
Post a Comment